Pharma major Zydus Cadila has received approval from the US FDA to market four products, including anti-depressant Escitalopram Oxalate tablets in US.

Zydus Cadila has received the US Food and Drug Administration (FDA) approval to market 10, 20, 40, 80 mg of Pravastatin Sodium tablets in the United States. It has also received tentative approval from the regulatory body to market Escitalopram Oxalate tablets (5, 10 and 20 mg), Losartam Potassium and Hydrochlorthiazide tablets (50mg/12.5 mg and 100 mg/25 mg) and Anastrazole tablets (1 mg) in the US, the filing said.

In 2007, the sale of anti-hypertensive Losartam Potassium and Hydrochlorthiazide tablets stood at 785 million dollar, while Anastrazole tablets had a market of 813 million dollar, the filling added.